$1,040 price target for Eli Lilly & Co. (LLY) stock

　　Eli Lilly produces brand-name prescription drugs to treat a wide range of medical conditions, including diabetes, cancer and neurological disorders. Analyst Sel Hardy says Lilly's GLP-1 (Zepbound) weight loss drug sales missed expectations in the most recent quarter, but he remains bullish on the stock in the long term given its large number of potential catalysts. Hardy is particularly optimistic that late-stage clinical drug candidates pirtobrutinib (for leukemia and lymphoma) and tirzepatide (for sleep apnea, kidney function and cardiology) will supplement Lilly's current core commercial drug portfolio. CFRA has a "buy" rating and $1,040 price target for LLY stock, which closed at $813.33 on Dec. 3.